YOU SEARCHED BY...
SEARCH BY...
Contract Service Directory
Country
- Argentina(1)
- Australia(7)
- Austria(1)
- Belgium(3)
- Canada(48)
- China(15)
- Colombia(1)
- Denmark(1)
- Finland(2)
- France(9)
- Germany(34)
- Greece(3)
- Hong Kong(1)
- Hungary(2)
- India(70)
- Ireland(1)
- Israel(2)
- Italia (6)
- Japan(1)
- Latvia(1)
- Luxembourg(1)
- Malta(1)
- Mauritius(1)
- Mexico(1)
- Peru(1)
- Poland(1)
- Portugal(3)
- Singapore(1)
- Slovenia(1)
- South Korea(4)
- Spain(9)
- Sweden(2)
- Switzerland(20)
- Taiwan(2)
- The Czech Republic(1)
- The Netherlands(4)
- Turkey(2)
- Ukraine(1)
- United Kingdom(46)
- United States(607)
- Vietnam(1)
Contract Service Directory
WuXi STA, STA Pharmaceutical, a subsidiary of WuXi AppTec
Company Headquarters
90 De Lin Lu
Waigaoqiao Free Trade Zone
Shanghai Shi 200137
China
Contract Service Directory
- CMC (Chemistry, Manfacturing & Controls)
- Contract Development and Manufacturing Organization (CDMO)
- Dosage Form Development
- Drug Development Services
- Formulation Development
- Manufacturing, API, High Potency
- Manufacturing, Aseptic Fill/Finish
- Manufacturing, Clinical Trials Supply
- Manufacturing, Lyophilized Products
- Manufacturing, Oligonucleotides
- Manufacturing, Peptides
- Manufacturing, Solid Dosage
- Preformulation
- Process Development/Scale-Up Services
- Spray Drying
Contract Services Directory
Related Content
-
Breaking News | cGMP Manufacture | Industry News
WuXi STA, Impact Therapeutics Enter Strategic Pact
WuXi STA will serve as Impact’s preferred contract development and manufacturing partner for its pipeline.11.21.19
-
Finalists Revealed for CPhI Worldwide’s 2019 Awards
Formulation and packaging categories were the most competitive.10.29.19
-
Breaking News | Facilities | Industry News | Inspections
WuXi STA’s Jinshan Facility Passes EMA Inspection
Five-day inspection covered 11 products approved by EMA in recent years.10.28.19
-
Industry News | Inspections | Regulatory Affairs
WuXi STA Facilities Pass U.S. FDA Inspections
Analytical Service Unit in Shanghai and API manufacturing facility in Changzhou successfully pass inspections07.24.19
-
Breaking News | Industry News | Inspections
WuXi STA Facilities Pass FDA Inspections
No Form 483s were issued at Shanghai and Changzhou sites07.23.19
-
cGMP Manufacture | Clinical Trial Materials | Industry News
Phoenix Molecular, WuXi STA Reach Drug Supply Milestone
Completes clinical trial supply to support Phase I/Ib study of PMD-026 for TNBC06.07.19
